Header

UZH-Logo

Maintenance Infos

Publications for Teigler-Schlegel, A

Navigate back| Up a level
Export as
Group by:
Number of items: 5.

2017

Locatelli, Franco; Valsecchi, Maria Grazia; Möricke, Anja; Zimmermann, Martin; Gruhn, Bernd; Biondi, Andrea; Kulozik, Andreas E; Silvestri, Daniela; Bodmer, Nicole; Putti, Maria Caterina; Burdach, Stefan; Micalizzi, Concetta; Teigler-Schlegel, Andrea; Ritter, Jörg; Pession, Andrea; Cario, Gunnar; Bielack, Stefan; Basso, Giuseppe; Klingebiel, Thomas; Vinti, Luciana; Rizzari, Carmelo; Attarbaschi, Andishe; Santoro, Nicola; Parasole, Rosanna; Mann, Georg; Karawajew, Leonid; Haas, Oskar A; Conter, Valentino; Schrappe, Martin (2017). Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood, 130(19):2146-2149.

2013

Dörge, Petra; Meissner, Barbara; Zimmermann, Martin; Moericke, Anja; Schrauder, Andre; Bourquin, Jean-Pierre; Schewe, Denis; Harbott, Jochen; Teigler-Schlegel, Andrea; Ratei, Richard; Ludwig, Wolf Dieter; Köhler, Rolf; Bartram, Claus R; Schrappe, Martin; Stanulla, Martin; Cario, Gunnar (2013). IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica, 98(3):428-432.

2011

Creutzig, U; Zimmermann, M; Bourquin, J P; Dworzak, M N; von Neuhoff, C; Sander, A; Schrauder, A; Teigler-Schlegel, A; Stary, J; Corbacioglu, S; Reinhardt, D (2011). Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood, 118(20):5409-5415.

2010

Pichler, H; Möricke, A; Mann, G; Teigler-Schlegel, A; Niggli, F; Nebral, K; König, M; Inthal, A; Krehan, D; Dworzak, M N; Janousek, D; Harbott, J; Schrappe, M; Gadner, H; Strehl, S; Haas, O A; Panzer-Grümayer, R; Attarbaschi, A (2010). Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. British Journal of Haematology, 149(1):93-100.

2009

Meyer, C; Kowarz, E; Hofmann, J; Renneville, A; Zuna, J; Trka, J; Ben Abdelali, R; Macintyre, E; De Braekeleer, E; De Braekeleer, M; Delabesse, E; de Oliveira, M P; Cavé, H; Clappier, E; van Dongen, J J M; Balgobind, B V; van den Heuvel-Eibrink, M M; Beverloo, H B; Panzer-Grümayer, R; Teigler-Schlegel, A; Harbott, J; Kjeldsen, E; Schnittger, S; Koehl, U; Gruhn, B; Heidenreich, O; Chan, L C; Yip, S F; Krzywinski, M; Eckert, C; Möricke, A; Schrappe, M; Alonso, C N; Schäfer, B W; Krauter, J; Lee, D A; Zur Stadt, U; Te Kronnie, G; Sutton, R; Izraeli, S; Trakhtenbrot, L; Lo Nigro, L; Tsaur, G; Fechina, L; Szczepanski, T; Strehl, S; Ilencikova, D; Molkentin, M; Burmeister, T; Dingermann, T; Klingebiel, T; Marschalek, R (2009). New insights to the MLL recombinome of acute leukemias. Leukemia, 23(8):1490-1499.

This list was generated on Tue Jun 25 02:52:09 2019 CEST.